Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.
| Condition | Intervention | Phase |
|---|---|---|
|
Bipolar 1 Disorder |
Drug: ELND005 Drug: Lamotrigine Drug: Valproic acid Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder |
- Time to recurrence of any mood episode [ Time Frame: up to 48 weeks ] [ Designated as safety issue: No ]
- Proportion of study participants with recurrence of any mood episode [ Time Frame: up to 48 weeks ] [ Designated as safety issue: No ]
- Time to recurrence of a depressive episode [ Time Frame: up to 48 weeks ] [ Designated as safety issue: No ]
- Time to recurrence of a manic/hypomanic or a mixed episode [ Time Frame: up to 48 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 400 |
| Study Start Date: | August 2012 |
| Estimated Primary Completion Date: | August 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Lamotrigine or Valproic acid + ELND005
Lamotrigine or valproic acid plus ELND005 film coated tablets, 500mg BID for up to 48 weeks
|
Drug: ELND005
Other Name: Scyllo-inositol
Drug: Lamotrigine
Drug: Valproic acid
|
|
Placebo Comparator: Lamotrigine or Valproic acid + placebo
Lamotrigine or valproic acid plus matched placebo BID for up to 48 weeks
|
Drug: Lamotrigine Drug: Valproic acid Drug: Placebo |
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Meets the DSM-IV-TR criteria for BPD I by the SCID, prior to the Screening Visit.
- Has a history in the last 3 years of ≥ 1 manic or mixed episodes of sufficient severity that required hospitalization and/or treatment with a mood stabilizer or antipsychotic, or confirmed by a family member or medical records to ensure the episode fulfills the DSM-IV-TR criteria.
- Has experienced a mood episode of any polarity within 4 months prior to the Screening Visit and responded to StOC therapy.
- Is euthymic at the Screening Visit (ie, score of ≤ 12 on the MADRS and a score of ≤ 12 on the Y-MRS).
- Is receiving maintenance treatment for his or her BPD I with either LTG or VPA; on stable doses for past 4 weeks and therapeutic drug levels (total VPA 50--125 µg/mL and LTG 10-50 µmol/L or as deemed appropriate by the investigator). Dose adjustments made for tolerability reasons will be acceptable.
A study patient must meet the following additional criteria to be eligible for randomization in the Double-blind Randomization Phase of this study:
- Maintained in a stable euthymic state during Phase 1, defined as Y-MRS and MADRS scores of ≤ 12, with the following exceptions: a maximum of 2 nonconsecutive excursions will be allowed throughout Phase 1. Excursions are defined as Y-MRS or MADRS scores >12 but ≤ 16.
Exclusion Criteria:
- Woman of childbearing potential who is unwilling or unable to use an acceptable method of birth control or is using a prohibited contraceptive method.
- Is found to be actively suicidal on the C-SSRS (answer of "yes" to question 4 or 5 [current or over the last 30 days]) or a score of ≥4 on the MADRS item 10 at the Screening Visit.
- Has suboptimally treated thyroid disease as evidenced by thyroid-stimulating hormone (TSH) >3 mIU/L at the Screening Visit.
- Has received electroconvulsive therapy (ECT) during the current episode or within 6 months prior to the Screening Visit.
- Has an estimated glomerular filtration rate <40 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease formula.
A study patient who meets ANY of the above and ANY of the criteria below will not be eligible for enrollment in the Double-blind Randomization Phase of this study:
- Has current signs or symptoms of psychosis.
- Has become actively suicidal as defined by C-SSRS answer of "yes" to question 4 or 5 (current or over the last 30 days) and/or has a score of ≥4 on MADRS item 10.
Contacts and Locations| Contact: Lisa Parsons | 503-432-1754 |
Hide Study Locations| United States, Alabama | |
| Elan Investigational Site | Recruiting |
| Birmingham, Alabama, United States, 35294 | |
| United States, Arizona | |
| Elan Investigational Site | Recruiting |
| Glendale, Arizona, United States, 85306 | |
| United States, Arkansas | |
| Elan Investigational Site | Recruiting |
| Little Rock, Arkansas, United States, 72211 | |
| Elan Investigational Site | Recruiting |
| Little Rock, Arkansas, United States, 72201 | |
| United States, California | |
| Elan Investigational Site | Recruiting |
| Cerritos, California, United States, 90703 | |
| Elan Investigational Site | Recruiting |
| Costa Mesa, California, United States, 92626 | |
| Elan Investigational Site | Recruiting |
| Escondido, California, United States, 92025 | |
| Elan Investigational Site | Recruiting |
| Garden Grove, California, United States, 92845 | |
| Elan Investigational Site | Recruiting |
| National City, California, United States, 91950 | |
| Elan Investigational Site | Recruiting |
| Oceanside, California, United States, 92056 | |
| Elan Investigational Site | Recruiting |
| Palo Alto, California, United States, 94304 | |
| Elan Investigational Site | Recruiting |
| Riverside, California, United States, 92506 | |
| Elan Investigational Site | Recruiting |
| San Diego, California, United States, 92121 | |
| Elan Investigational Site | Recruiting |
| Santa Ana, California, United States, 92701 | |
| United States, Connecticut | |
| Elan Investigational Site | Recruiting |
| Norwich, Connecticut, United States, 06360 | |
| United States, Florida | |
| Elan Investigational Site | Recruiting |
| North Miami, Florida, United States, 33161 | |
| Elan Investigational Site | Recruiting |
| Tampa, Florida, United States, 33613 | |
| United States, Georgia | |
| Elan Investigational Site | Recruiting |
| Atlanta, Georgia, United States, 30308 | |
| Elan Investigational Site | Recruiting |
| Roswell, Georgia, United States, 30076 | |
| United States, Missouri | |
| Elan Investigational Site | Recruiting |
| Creve Coeur, Missouri, United States, 63141 | |
| Elan Investigational Site | Recruiting |
| St. Louis, Missouri, United States, 63118 | |
| Elan Investigational Site | Recruiting |
| St. Louis, Missouri, United States, 63141 | |
| Elan Investigational Site | Recruiting |
| St. Louis, Missouri, United States, 63128 | |
| United States, Nebraska | |
| Elan Investigational Site | Recruiting |
| Lincoln, Nebraska, United States, 68526 | |
| United States, New Jersey | |
| Elan Investigational Site | Recruiting |
| Marlton, New Jersey, United States, 08053 | |
| United States, New York | |
| Elan Investigational Site | Recruiting |
| Fresh Meadows, New York, United States, 11366 | |
| Elan Investigational Site | Recruiting |
| New York, New York, United States, 10065 | |
| United States, North Carolina | |
| Elan Investigational Site | Recruiting |
| Raleigh, North Carolina, United States, 27609 | |
| United States, Ohio | |
| Elan Investigational Site | Recruiting |
| Beachwood, Ohio, United States, 44122 | |
| Elan Investigational Site | Recruiting |
| Cincinnati, Ohio, United States, 45219 | |
| Elan Investigational Site | Recruiting |
| Cleveland, Ohio, United States, 44106 | |
| United States, Oklahoma | |
| Elan Investigational Site | Recruiting |
| Oklahoma City, Oklahoma, United States, 73112 | |
| United States, Pennsylvania | |
| Elan Investigational Site | Recruiting |
| Philadelphia, Pennsylvania, United States, 19139 | |
| United States, South Carolina | |
| Elan Investigational Site | Recruiting |
| Charleston, South Carolina, United States, 29407 | |
| United States, Texas | |
| Elan Investigational Site | Recruiting |
| Hurst, Texas, United States, 76053 | |
| Elan Investigational Site | Recruiting |
| San Antonio, Texas, United States, 78229 | |
| United States, Utah | |
| Elan Investigational Site | Recruiting |
| Salt Lake City, Utah, United States, 84106 | |
| United States, Washington | |
| Elan Investigational Site | Recruiting |
| Bellevue, Washington, United States, 98007 | |
| Bulgaria | |
| Elan Investigational Site | Recruiting |
| Kardzhali, Bulgaria, 6600 | |
| Elan Investigational Site | Recruiting |
| Pazardzhik, Bulgaria, 4400 | |
| Elan Investigational Site | Recruiting |
| Vratsa, Bulgaria, 3000 | |
| Canada, Alberta | |
| Elan Investigational Site | Recruiting |
| Edmonton, Alberta, Canada, T6L 6W6 | |
| Canada, British Columbia | |
| Elan Investigational Site | Recruiting |
| Kelowna, British Columbia, Canada, V1Y 1Z9 | |
| Canada, Nova Scotia | |
| Elan Investigational Site | Recruiting |
| Halifax, Nova Scotia, Canada, B3H 2E2 | |
| Canada, Ontario | |
| Elan Investigational Site | Recruiting |
| Chatham, Ontario, Canada, N7M 5L9 | |
| Elan Investigational Site | Recruiting |
| Kingston, Ontario, Canada, K7L 4X3 | |
| Czech Republic | |
| Elan Investigational Site | Recruiting |
| Brno, Czech Republic, 602 00 | |
| Elan Investigational Site | Recruiting |
| Litomerice, Czech Republic, 41201 | |
| Elan Investigational Site | Recruiting |
| Praha, Czech Republic, 18100 | |
| Elan Investigational Site | Recruiting |
| Praha, Czech Republic, 120 00 | |
| Elan Investigational Site | Recruiting |
| Praha, Czech Republic, 100 00 | |
| Lithuania | |
| Elan Investigational Site | Recruiting |
| Kaunas, Lithuania, 50009 | |
| Romania | |
| Elan Investigational Site | Recruiting |
| Brasov, Romania, 500366 | |
| Elan Investigational Site | Recruiting |
| Bucharest, Romania, 041914 | |
| Elan Investigational Site | Recruiting |
| Craiova, Romania, 200473 | |
| Elan Investigational Site | Recruiting |
| Sibiu, Romania, 550082 | |
| Spain | |
| Elan Investigational Site | Recruiting |
| Torrevieja, Alicante, Spain, 03186 | |
| Elan Investigational Site | Recruiting |
| L'Hospitalet, Barcelona, Spain, 08907 | |
| Elan Investigational Site | Recruiting |
| Barcelona, Spain, 08036 | |
| Elan Investigational Site | Recruiting |
| Madrid, Spain, 28034 | |
| Elan Investigational Site | Recruiting |
| Vitoria, Spain, 01004 | |
More Information
No publications provided
| Responsible Party: | Elan Pharmaceuticals ( Elan Pharma International Limited ) |
| ClinicalTrials.gov Identifier: | NCT01674010 History of Changes |
| Other Study ID Numbers: | ELND005-BPD201, 2012-001935-30 |
| Study First Received: | August 24, 2012 |
| Last Updated: | June 11, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Lamotrigine Valproic Acid Anticonvulsants Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action GABA Agents |
Neurotransmitter Agents Physiological Effects of Drugs Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Calcium Channel Blockers Membrane Transport Modulators Cardiovascular Agents |
ClinicalTrials.gov processed this record on June 18, 2013